Summit Therapeutics' Ivonescimab Shows Consistent Survival Benefits Across Global NSCLC Trial — Summit Therapeutics Inc.

Event summary

Updated Phase III HARMONi trial data show ivonescimab plus chemotherapy achieved a statistically significant overall survival (OS) benefit in EGFR-mutated NSCLC patients, with a hazard ratio of 0.76 (p=0.0151).
Consistent OS results observed across Western and Asian patient subgroups, with median follow-up extending to 23.2 months for Western patients and 32.7 months for Asian patients.
Summit Therapeutics' Biologics License Application (BLA) for ivonescimab in the U.S. has a PDUFA goal action date of November 14, 2026.
Additional positive data from the HARMONi-2 trial in China showed ivonescimab monotherapy outperformed pembrolizumab in OS for PD-L1-positive NSCLC patients.

The big picture

Summit Therapeutics' updated HARMONi trial data reinforce ivonescimab's potential as a differentiated bispecific antibody in EGFR-mutated NSCLC, addressing a critical unmet need for patients who progress on third-generation EGFR TKIs. The consistent OS benefits across diverse patient populations position the therapy for potential regulatory approval and commercialization in a lucrative oncology market. The broader clinical program, including trials in biliary tract cancer and other solid tumors, underscores Summit's ambition to expand ivonescimab's therapeutic reach beyond lung cancer.

What we're watching

Regulatory Approval: Whether the FDA will grant approval for ivonescimab by the November 14, 2026 PDUFA date, based on the updated HARMONi trial data.
Commercial Strategy: How Summit Therapeutics plans to position ivonescimab in the competitive EGFR-mutated NSCLC market, particularly against established therapies like osimertinib.
Clinical Expansion: The pace at which Summit will advance ivonescimab into additional indications, including biliary tract cancer and other solid tumors, following the positive HARMONi-2 results.